ARTICLES BY LOUIS

• Drug Tariffing: How Trade Policy And Politics Manipulate Your Outsourcing

  6/8/2020

  Tariffs, historic trade policy, politics: Most likely not top-of-mind right now. Here’s why they should be, particularly for younger professionals at U.S. biotechs leveraging CDMOs.

• The Oral Solid Dose Path To U.S. Partnerships

  5/28/2020

  OSD drugs are receiving the benefits of new technologies, formulation ideas, and other processing innovations. Can innovation pare COGs to open up more production in the U.S.? Here's our assessment.

• Common Drugs Now Made In America!

  5/22/2020

  It begins in a typical flash hurled by our hyrdoxycloriquine President. A U.S. drug manufacturer gets up to $812 million in federal funding for advanced manufacturing of America's most essential medicines. More politics or real progress?

• Circle Economics And A Man Made In America

  5/21/2020

  Inspiration and "circle economics" could help shape your outsourcing decisions. And who knows: It all might end up supporting a more robust national drug-manufacturing infrastructure.

• View From Tokyo: Rise Of The “Values” Chain

  5/15/2020

  The Wuhan coronavirus outbreak has brokered a virulent "value" chain debate around the world, including a global CDMO's CEO situated in Tokyo. 

• Pfizer Shifts Outsourcing And Communication To Fight COVID-19

  5/14/2020

  Pfizer’s speaking in real-time – actually forward-looking pronouncements of manufacturing intentions and locations – is refreshing, and should be applauded. Does this represent an industry "shift"?

• As Your CDMOs Grow In Value, Their Challenges Pile Up

  5/11/2020

  The CDMO market is estimated to grow to $157.7 billion in 2025, a compound annual growth rate (CAGR) of 6.9%, according to an industry report. But what kind of CDMO growth is best for Outsourced Pharma readers?

• The Raw Materials Of A Supply-Chain Revolution

  5/6/2020

  To diversify China-dependent supply chains and procure materials, API and products in the U.S., we'd literally need to start digging.

• Question Your Buyer Motivation And Supply-Chain Origins

  5/1/2020

  Don Buckner left a comment to my recent '50 By 25" editorial: “Will have success if the buyers demand it.” I liked the idea of buyer-driven demand as a path to explore your supply-chain decisions. It also led to some fundamental questions of your motivations.

• A COVID-19 Vaccine, Outsourcing, And Made In The USA

  4/27/2020

  That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.